Abstract: Increases in arterial blood pressure cause cumulative changes in tissue structure and function, resulting ultimately in end-organ damage. One of the pathological hallmarks of hypertensive tissue injury is an increase in tissue fibrosis, which leads to reductions in tissue compliance and function. Fibrosis (or sclerosis) occurs as result of marked changes in the amount and composition of the extracellular matrix. This extracellular matrix is a complex mixture of structural proteins and glycoproteins, including collagens, fibronectins, and proteoglycans. Hypertension is known to be associated with increases in the synthesis of extracellular matrix proteins and changes in their degradation. These processes are mediated by several mediators, in particular the renin-angiotensin-aldosterone system. Since these changes play an important role in the formation of vascular sclerosis, cardiac dysfunction, and renal damage, understanding the mechanisms, and finding interventions to prevent or reverse these changes are clinically important. In this review we discuss the alterations in the extracellular matrix during hypertension, as well as the effects of antihypertensive agents in animal models and human patients.
INTRODUCTION
Hypertension is a major risk factor for cardiovascular disorders such as stroke, heart failure, vascular disease, and end-stage renal disease, and is a leading cause of morbidity and mortality worldwide. Since blood pressure is determined by both cardiac output and peripheral vascular resistance, it has been speculated that a contributing factor to the pathogenesis of hypertension is an increase in total peripheral resistance resulting from a structural reduction in the caliber of the small resistance arteries and arterioles. Understanding the morphological changes in the vasculature (vascular remodeling) may therefore be important for understanding the pathogenesis of this disease, particularly in animal models such as the spontaneously hypertensive rat (SHR). In addition, many of the complications of hypertension, such as stroke, coronary heart disease, and aneurysm formation are themselves a direct result of the vascular damage induced by prolonged blood pressure elevation. Therefore, the vascular remodeling associated with hypertension may contribute both to the pathogenesis of its hypertension and to its pathophysiological consequences.
Hypertensive end-organ damage in the myocardium and the renal glomeruli is also characterized by the appearance of fibrosis (also referred to as sclerosis). Fibrosis is caused by the accumulation of extracellular matrix (ECM) proteins, such as collagens. Although accumulation of ECM may be adaptive (physiological) initially, excess accumulation leads to decreases in tissue compliance and function. For example, the accumulation of collagen in the heart wall may be adaptive at first, but when uncontrolled leads to a loss of wall compliance, and eventually to heart failure. Similarly, accumulation of ECM in the glomeruli (glomerulosclerosis) *Address correspondence to this author at the Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan; Tel: 81-3-3353-1211; Fax: 81-3-3359-2745; E-mail: sasamura@sc.itc.keio.ac.jp leads directly to a loss of glomerular filtration capacity. Understanding the changes in ECM production and degradation in hypertension may therefore be important when considering new strategies for the prevention and treatment of hypertension and its complications. In this review, we will examine the changes in ECM in hypertension, focusing principally on the vasculature, but will also overview the changes the heart and renal glomeruli, whenever these are relevant to hypertensive disease and its treatment. We will also examine the effects of antihypertensive agents on ECM remodeling, which may be important for understanding the organ-protective effects of these agents.
Components of the ECM
The ECM is a complex mixture of macromolecules, which envelops virtually all the cells of the body [1] [2] [3] . It has been estimated that about 30% of body proteins are present in the ECM. The ECM may be broadly classified into three major types: structural proteins such as collagen and elastin, specialized and adhesive proteins such as fibronectin and laminin, and proteoglycans/glycosaminoglycans ( Table 1) .
Both collagens and elastins are fibrous molecules which supply the main protein content of vessels. Types I and types III collagens form the bulk of vascular collagens (60% and 30% respectively), while the remaining 10% includes types IV, V, VI, VIII, XII, XIV collagens [4] . Type I collagen is most prevalent in the adventitia of the rat aorta, whereas type III collagen is found in the media and adventitia [5] . In humans, types I and III have been detected in the intima, media, and adventitia [6] . Both these collagens are important for providing tensile strength to the tissues. In the heart, the major fibrillar collagens in the adult are also types I and III, with the ratio of type I to type III in the order of 1.3-1.9:1 [7] . These collagens are also the major collagen types found in the renal interstitium, but are usually not present in normal human glomeruli [8] . In contrast, type IV collagen is an important structural feature in the glomerulus, since it is a principal component of the glomerular basement membrane. Types V and VI collagen are also found in the glomerular mesangium [9] . In terms of molecular structure, the collagens are synthesized primarily as a homotrimeric (e.g. Type III) or heterotrimeric (e.g. Type I) procollagen chains. The procollagen is processed extracellularly by N-and Cproteinases to produce the characteristic triple-helical molecule which is associated with the distinct mechanical properties of this macromolecule.
While collagens are the major source of tensile strength, elastin provides elasticity to tissues. Elastin is the major component of the ECM in the vasculature and can comprise up to 50% of its dry weight [10] . In the large arteries in particular, elastin is the most abundant protein, which reflects the fact that these arteries are continuously subjected to severe pulsatile pressure generated by cardiac contraction. Elastin is also detectable in the resistance arteries, mainly in the internal and external elastic lamina.
Elastin is initially synthesized in a single polypeptide form as tropoelastin, which is the soluble precursor of elastin [1] . Individual chains are secreted into the extracellular space, where they associate with other microfibrillar glycoproteins such as fibrillins and microfibrillar-associated glycoproteins (MAGPs) to form elastic fibers. During vessel development, the elastic fibers are arranged into concentric rings of elastic lamellae alternating with rings of vascular smooth muscle cells around the arterial lumen. This elastic lamella provides the elasticity to absorb the hemodynamic stress of cardiac systole, and to release this energy in the form of sustained blood pressure during diastole [10] .
The fibrous proteins collagen and elastin are embedded in a gel-like ground substance composed of proteoglycans/ glycosaminoglycans [11] . With the exception of hyaluronan, which lacks a core protein, these glycoproteins consist of a central core protein bound to one or more glycosaminoglycan (GAG) side-chains. A characteristic feature of these macromolecules is their high capacity to bind to water molecules as well as a variety of other chemical substances [12] . The heterogeneity of proteoglycan structure is a reflection not only of the large number of different core proteins, but also the potential variety in the type and size of the GAG chains, which can contain chondroitin sulfate, dermatan sulfate, heparan sulfate, or keratan sulfate moieties.
The proteoglycans have multiple functions which may be of relevance to hypertensive disease. Proteoglycans such as decorin are associated with collagens at specific binding sites, and are required for the normal formation of collagen fibrils [12] . Proteoglycans also have functional roles related both to their direct actions to regulate cell growth, migration, adhesion, and proliferation, and via their ability to bind and/or activate and inactivate growth factors and cytokines involved in the regulation of ECM synthesis and degradation. In the basement membrane, proteoglycans (principally heparan sulfate proteoglycans such as perlecan) form a charge barrier to the passage of negative charged proteins, since the GAG chains themselves have a high negative charge which serves to repel such molecules. In addition, proteoglycans in the blood vessel may be involved in lipoprotein retention and may therefore play a key role in the processes of atherosclerosis [13] .
Both structural proteins and proteoglycans are known to be associated with adhesive proteins, a term which includes such molecules as fibronectin, vitronectin, laminin and thrombospondin [14] . Many of these proteins possess short aspartate-containing sequences such as Arg-Gly-Asp, which mediate cellular adhesion through the integrin family of membrane receptors. The adhesive proteins can interact in turn with other ECM molecules, so that the ECM surrounding the body's cells form a structural scaffold which maintains the tissue framework. The adhesive and other specialized glycoproteins may also be involved in the regulation of tissue morphology and function, and in the control of deposition of other ECM through protein-protein interactions [15] .
REGULATION

OF ECM SYNTHESIS AND DEGRADATION
Although fibroblasts are a major source of ECM synthesis, the ECM components may also be synthesized by other cellular components of the cardiovascular system, including vascular smooth muscle cells, endothelial cells, mesangial cells, cardiomyocytes, and infiltrative cells. The synthesis of ECM by these cells is governed by both mechanical stimuli and biochemical stimuli. Changes in mechanical stimuli (for example, shear stress or stretch) may be triggered by acute changes in blood flow and pressure. Vasoactive hormones and mediators, together with local growth factors and cytokines play a key intermediary role in converting changes in blood pressure to the adaptive changes in the ECM. As shown in (Table 2) , multiple systemic and local factors may be involved in the processes of ECM remodeling in hypertension. In all tissues, the ECM content at any time is regulated by the balance between ECM synthesis and degradation [2] . One of the principal sites of regulation of ECM synthesis occurs at the promoter (gene transcription) level, resulting in changes in mRNA levels, which translate into changes in the synthesis of the ECM protein. Other potential sites of regulation of ECM synthesis include control of posttranslational modifications, control of secretion, and control of ECM assembly.
On the other hand, ECM degradation is controlled by a variety of enzymes including matrix metalloproteinases (MMPs), serine proteases and cysteine proteases [2] , [16] . Physiological regulation of ECM degradation is due in a large part to the actions of MMPs, and it has been estimated that MMP-1 alone may account for the degradation of up to 40% of the newly synthesized collagen in different tissues [16] . These MMPs constitute a multigene family of zinc-and calcium-dependent endopeptidases which can degrade collagens and other ECM components with different specificities [17] . A list of the major metalloproteinases involved in cardiovascular remodeling and their putative substrates is presented in (Table 3) .
In general, MMPs are secreted from the cell as inactive precursors, which are then activated by proteases such as plasmin, or by the action of cell-associated membrane-type MMPs. The activity of MMPs is regulated at multiple levels: at the gene transcription level, at the level of posttranslational modification of inactive precursors, by the activation of inactive precursors into the active enzyme, and by interactions of secreted MMPs with local tissue inhibitors of metalloproteinases (TIMPs) which can bind to, and modulate, MMP activity [18] .
CHANGES IN ECM CONTENT IN HYPERTENSION Vascular Changes
In terms of vascular morphology, hypertension leads to an increase in the diameter and the intima-media thickness in the large elastic and muscular arteries. In the case of the small muscular resistance arteries and arterioles, essential hypertension is associated with a decrease in the lumen diameter and an increase in the media-to-lumen ratio of resistance vessels [19, 20] . With mild-moderate hypertension, this alteration involves a rearrangement of the vascular structure, such that the arterial wall cross-sectional area is not changed, whereas the lumen is reduced ('eutrophic remodeling'). In the case of severe hypertension or in forms of secondary hypertension, hypertrophy of the vascular wall results in an increase in the arterial wall cross-sectional area together with a decrease in lumen diameter ('hypertrophic remodeling'). These changes are found both in human subjects and in animal models of hypertension [21] .
In biochemical terms, a rapid and sensitive ECM response to the elevated wall stress in hypertension is an increase in elastin synthesis [22] . Pressure-induced stretch may trigger this response, since cultured VSMC can be elicited to increase elastin synthesis by applying a weight to culture dishes with deformable bottoms [23] .
Collagen, the other fibrous component of the vascular ECM, is also increased after the initiation of hypertension. Xu et al. established a mid-thoracic aortic coarctation in the rabbit, and found that gene expression for types I and III collagen were rapidly increased, but returned to normal by 4-8 weeks [24] . In the case of both elastin and collagen, the increase in synthesis after blood pressure elevation appears to be attenuated as soon as the blood pressure stops rising. However, the metabolic turnover of mature collagen and elastic fibers is relatively low, and the content of collagen+ elastin may remain increased in hypertensive patients as well as in animal models of hypertension. If the accumulation of vascular collagen leads to excessive stiffness, this would be maladaptive, since increased stiffness of conduit arteries, as evidenced by increases in pulse pressure and pulse-wave velocity, is in itself an independent risk factor for cardiovascular disease, specially for stroke [25] .
In concert with the increases in structural proteins, changes in other ECM components such as proteoglycans and other glycoproteins also occur in hypertension. Lipke et al. reported that proteoglycan synthesis in vessels exposed to hypertension was increased 4 days after the production of aortic coarctation, whereas proteoglycan synthesis in other vessels was unaffected, suggesting a direct effect of pressure. Interestingly, after 14 days, proteoglycan synthesis was increased even in vessels not directly exposed to hypertension, suggesting the involvement of pressureindependent mechanisms at the latter time point [26] . Fibronectin synthesis is also increased in the aorta of both genetically hypertensive rats, and rats made hypertensive by treatment with deoxycorticosterone/salt [27] .
Changes may also occur in the vascular MMP system as a result of hypertension. Immunocytochemical studies on nondiseased human arteries, and arteries from experimental animals suggest the expression of MMP-2, TIMP-1, and TIMP-2 in normal arteries [28] . MMP-1 and MMP-7 may also be expressed at low levels. In general, MMP enzymatic activity is not detectable, suggesting that their activity is tonically repressed by the TIMPs. In diseased arteries, and arteries with atherosclerosis, MMP expression and activity is increased. Moreover, when porcine arteries ex vivo are subjected to an elevation of transmural pressure, an increase in MMP-2 and MMP-9 activities are seen [29] . Similar results have been reported in vitro, namely, cyclical mechanical strain to simulate blood pressure changes results in an increase in MMP-2 activity in human VSMC, rather than a decrease [30] . It could be hypothesized that this increase in MMP activity is a compensatory response designed to limit excess ECM accumulation. Further studies are required to delineate more clearly the role that individual MMPs play in the processes of vascular remodeling in hypertension.
Cardiac Changes
In the heart, increased wall pressure results in an increase in wall tension and stress, and increases in ECM components may be a response to that stress. Studies performed with postmortem human hearts and with endomyocardial human biopsies have shown that the amount of fibrillar collagen is increased in the myocardium of patients with hypertensive heart disease compared with normotensive controls [31] . The proteoglycan biglycan, and the adhesive proteins fibronectin and laminin are also increased in hearts with pressure overload [32, 33] . Excess accumulation of ECM components (cardiac fibrosis) raises myocardial stiffness, thus compromising diastolic function, while further accumulation may impair myocardial contraction and systolic function.
The increase in wall stress itself is probably the initial stimulus for excess collagen deposition and fibrosis. In vitro studies have shown that cyclic mechanical load can stimulate procollagen type I synthesis in cardiac fibroblasts [34] . These changes may be mediated either directly or indirectly through the involvement of other vasoactive peptides, cytokines, and growth factors such as TGF-β. Changes in the collagenolytic pathways (MMPs and TIMPs) could also play a subsidiary role, since MMP-1 activity has been reported to be depressed in the ventricular biopsies of patients with cardiac hypertrophy [35] . When dog hearts were subjected to chronic pressure overload secondary to aortic banding, myocardial MMP-1 levels were reduced whereas MMP-1/TIMP-1 complex formation was increased [36] . In vitro studies using cardiac fibroblasts have also shown that MMP-1 expression in cardiac fibroblasts is reduced by cyclic stretching [34] .
Serum Markers of Cardiovascular ECM Synthesis and Degradation in Hypertension
New assays for collagen fragment peptides have been used by several groups for non-invasive assessment of cardiovascular collagen synthesis and degradation in hypertensive patients. The type 1 procollagen carboxyterminal peptide (PIP) and type III collagen amino-terminal peptide (PIIIP) are produced during the synthesis of collagen fibrils, and measurement of these components have been utilized to estimate cardiovascular production of these collagens. In contrast, the carboxy-terminal telopeptide of collagen type I (CITP) is considered a marker of degradation of type I collagen. In rats with genetic hypertension, serum PIP levels were significantly increased, and importantly, the serum PIP was found to be directly correlated to ventricular collagen volume fraction [37] . Diez et al. also reported that patients with essential hypertension have high levels of PIP and PIIIP compared to normotensive patients [38] . In contrast, the same group reported that free MMP-1 levels were reduced, and free TIMP-1 levels were increased in hypertensive patients [39] . These changes were reversed after therapy with ACEI. Consistent data have been reported reported that MMP-2 and MMP-9 levels were decreased in the plasma of patients with essential hypertension, and that 6 month treatment with amlodipine can normalize MMP-9 but not MMP-2 [43] . Although it is still unclear whether the changes seen in the serum accurately reflect the situation in the heart and vasculature, these markers could potentially provide information concerning changes in ECM synthesis and degradation in individual patients.
Renal Changes
Hypertensive nephrosclerosis is reported to be the second leading cause of end-stage renal disease (ESRD) in the USA. Although there is debate about whether hypertension alone is a major cause of ESRD [44] , available evidence suggests that hypertension will contribute to the progression of chronic renal disease [45] . A common feature of hypertensive nephrosclerosis, aside from the renal vascular changes, is the accumulation of ECM in the renal glomeruli (glomerular sclerosis), which leads to a decline in glomerular filtration rate. The components of the ECM which may accumulate in glomerular sclerotic lesions of different etiologies include types I, III, IV, V, VI collagens, fibronectin, laminin, and proteoglycans [9] , [8] .
Hypertension may contribute to glomerular sclerosis, if the pathophysiological condition is such that the intraglomerular pressure is raised, resulting in increased stretching of the glomerular components. It has been shown that stretching of mesangial cells leads to an increase in synthesis of collagens, fibronectin, and laminin in glomerular mesangial cells [46] . Growth factors (in particular TGF-β) may play a major role in transducing the mechanical changes to changes in the ECM. If increased systemic blood pressure alone causes the sclerotic changes, it would be expected that all hypertensive agents have similar effects in attenuating the progression of renal dysfunction. However a large body of evidence from clinical trials suggests that inhibition of the renin-angiotensin system (RAS) may be superior in ameliorating renal disease progression, independent of its effects on hypertension [47] . These findings are analogous to similar findings in the heart and vasculature. Although the reasons for the observed differences may be multifold, with effects on glomerular hemodynamics playing the major role in the kidney, some of the potential differences between inhibitors of the RAS and other antihypertensive agents with respect to ECM synthesis and degradation will be considered in the next section.
Effects of Antihypertensive Agents on the ECM
RAS
Inhibitors (Angiotensin-Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor Blockers (ARB))
Although the details are still a subject of debate, data from large clinical studies suggest that RAS inhibitors may have organ-protective effects over and above their hypotensive effects [48] . These results are compatible with animal experiments suggesting the importance of angiotensin II in mediating hypertension-induced tissue damage, includeing tissue sclerosis. The renin-angiotensin-aldosterone system (RAAS) may be involved in the control of tissue fibrosis through multiple pathways involving the modulation of both ECM synthesis and degradation, as outlined in (Fig. 1) .
In terms of ECM synthetic pathways, studies from our and other laboratories have shown that angiotensin II increases collagen synthesis in VSMC, and that both the type 1 and type 2 angiotensin receptors may be involved in these changes [49] [50] [51] . It has also been shown that angiotensin II increases fibronectin and proteoglycan synthesis both in vitro, and in vivo [52] [53] [54] [55] . Conversely, inhibiting angiotensin II production or action with ACEI or ARB decreases types I, II, IV collagen, fibronectin, laminin, and proteoglycan synthesis [56, 57] . Therefore in rats, anti-hypertensive treatment with ACEI or ARB causes a regression of the vascular media to lumen ratio, associated with decreased arterial stiffness and collagen/elastin ratios [58] . Similar findings have been reported in essential hypertensive patients treated with ACEI [19] . Comparable findings have been reported for the action of angiotensin II in the heart and kidneys, namely angiotensin II increases ECM synthesis in cardiac fibroblasts and mesangial cells in vitro, whereas ACEI or ARB attenuates ECM synthesis and accumulation in vivo and in human studies [56] , [59] , [7] .
Concerning the mechanisms of the effects of angiotensin II on ECM synthesis, both direct and indirect actions have been proposed. Asides from a potential direct action of angiotensin II on ECM synthesis, angiotensin II has been shown to induce the expression of growth factors and cytokines such as TGF-β, PDGF, FGF, and inhibition of these growth factors results in modulation of angiotensin IIinduced growth responses [60] . Therefore multiple pathways may contribute to the effects of angiotensin II on ECM synthesis.
In terms of ECM degradative pathways, angiotensin II has been reported to reduce MMP-1 activity in human cardiac fibroblasts [61] . Moreover angiotensin II enhances TIMP-1 production in rat heart endothelial cells [7] . Conversely, the ARB losartan has been reported to increase collagenase activity and decrease TIMP-1 expression in spontaneously hypertensive rats, leading to reversal of cardiac fibrosis [62] . The effects of angiotensin II on MMP activity are less clear-cut in the vasculature and the kidney, and further studies are required to clarify the effects of angiotensin II on individual MMPs and TIMPs in these tissues.
Aldosterone Antagonists
The Randomized Aldactone Evaluation Study (RALES) highlighted the fact that blockade of aldosterone receptors by spironolactone in addition to standard therapy (including ACEI) substantially reduces the risk of morbidity among patients with severe congestive heart failure [63] . The contribution of changes in ECM turnover to these findings was examined by Zannad et al., who found that both procollagen type I N-terminal peptide (PINP) and procollagen type III N-terminal peptide (PIIINP) levels were decreased after 6 months of spironolactone therapy, whereas these markers remained unchanged in the placebo group [64] . Similarly, Sato et al. reported that a combination of spironolactone and ACEI caused a significant reduction in serum PIIINP, and that changes in PIIINP were significantly correlated with changes in the left ventricular mass index in hypertensive patients [65] . These findings are consistent with animal studies which show that aldosterone inhibition using spironolactone can limit cardiac collagen accumulation in models of renovascular and aldosterone hypertension [66] . These effects may be additive with ACE inhibitors [67] or ARBs [68] . Similarly in the vasculature, aldosterone blockade has been reported to reduce vascular injury in animal models [69] , and to reduce collagen turnover in the blood vessels of patients with heart failure [70] . A similar beneficial effect on the vasculature has been observed with a selective aldosterone receptor antagonist eplerenone [71] . The mechanisms for these changes probably involves inhibition of the direct action of aldosterone on collagen synthesis [72] .
Calcium Channel Blockers
Although the results are open to multiple interpretations, recent clinical trials such as the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial suggest that calcium channel blockers may be as effective as RAS inhibitors in lowering blood pressure and reducing the risk of cardiovascular events [73] . Concerning the effects of these agents on the ECM, it has been reported by Ramires et al. that calcium channel blockade attenuates myocardial fibrosis associated with aldosterone or angiotensin II administration [74] , suggesting that these agents can attenuate the effects of the RAAS on tissue fibrosis in vivo. Calcium channel blockers have also been shown to inhibit collagen synthesis in vitro, in fibroblasts [75] and mesangial cells [76] . Potential mechanisms for these changes could involve interactions with endothelin gene expression [77] or prostaglandins [78] . Of interest, the calcium channel blocker isradipine has been reported to affect matrix synthesis by a mechanism independent of calcium channel blockade [79] . This suggests that there may be effects of calcium channel blockers which are unrelated to a class effect, resulting in potential heterogeneity of actions of individual calcium channel blockers on ECM remodeling. On the other hand, Rajzer et al. reported that neither the calcium channel blocker amlodipine nor the ARB losartan caused a significant effect on PWV or plasma PIP, whereas the ACEI quinapril decreased these parameters in patients with mildto-moderate arterial hypertension [80] . These results point to the need for further studies to clarify the effects of individual calcium channel antagonists on ECM remodeling, particularly in comparison to RAAS inhibitors.
Diuretics
The effects of diuretics on ECM remodeling have not been extensively studied, and the available reports are somewhat inconclusive. Contard et al. examined the effects of indapamide and hydrochlorothiazide on fibronectin expression in the coronary arteries of SHRSP, and found that expression of the fibronectin isoform EIIIA-FN was reduced by both these diuretics, whereas medial hypertrophy was prevented by hydrochlorothiazide but not indapamide [81] . In SHR on a high-salt diet, Et-Taouil et al. found that Fig. (1) . Potential interactions between the renin-angiotensin-aldosterone system (RAAS) and extracellular matrix (ECM) synthetic/degradative pathways. *Changes in parentheses represent changes caused by angiotensin II stimulation.
+ Angiotensin II has been reported to reduce heparan sulfate proteoglycans and increase MMP synthesis in some tissues.
indapamide had no significant effect on elastin, but increased the elastin/collagen ratio, suggesting attenuation of collagen synthesis [82] . On the other hand, Contri et al. reported that indapamide attenuated aortic fibrosis when administered concomitantly with the ACE inhibitor delapril in the aortas of salt-loaded SHRSP [83] . In a clinical study, Lopez et al. examined the effects of loop diuretics in patients with chronic heart failure, and found that serum PIP levels and collagen volume fraction in right septal endomyocardial biopsy specimens was reduced in patients treated with torasemide but not furosemide [84] . In animal experiments, furosemide was found to have no significant effect on cardiac collagen in post-infarction heart failure rat hearts [85] , whereas amiloride reduced cardiac collagen deposition in the hearts of DOCA-salt hypertensive rats [86] .
Adrenergic Receptor Blockers
The effects of alpha-and beta-adrenergic receptor blockers appear to differ. In vitro, stimulation of the alpha1-adrenergic receptor enhanced collagen and fibronectin production, and TGF-β mRNA expression in VSMC, whereas these parameters were inhibited by beta1-adrenergic stimulation [87] . In vivo, the alpha-adrenergic blocker doxazosin has been reported both to reduce vascular ECM content, and also to have no significant effect [88] , [53] . The beta-adrenergic blocker metoprolol has been reported to have no effect on the media:lumen ratio of hypertensive rats [89] . Interestingly, the beta-adrenergic receptor blocker carvedilol may differ from metoprolol, since it was reported to decrease expression of types I and III collagen, laminin, and fibronectin in rat hearts with chronic pressure overload, whereas metoprolol had no significant effect, suggesting different effects within the same class of antihypertensive agent [90] .
Other Agents
Although endothelin receptor antagonists are not strictly anti-hypertensive agents, they have been reported to have several favorable effects on tissue fibrosis. Endothelin receptor antagonism has been reported to be efficacious for the regression of renal vascular fibrosis [91] , and to decrease left ventricular collagen accumulation in rats with chronic heart failure [92] . These effects may be mediated by antagonizing the effects of endothelin to enhance collagen synthesis [93] . Furthermore, endothelin-1 infusion has been reported to increase cardiac MMP-2 activity, so the effects on ECM accumulation may be mediated at least in part by changes ECM degradative pathways [94] .
Future Perspectives
Since hypertension undoubtedly causes vascular structural changes which could lead to increased vascular resistance, it could be hypothesized that this increased vascular resistance exacerbates the hypertension resulting in a vicious circle favoring the maintenance of increased blood pressure [95, 96] [20] . One important consequence of these effects of ACEI and ARB on vascular structure is that these agents may cause a decrease in renal afferent arteriole media cross-sectional areas and consequently a decrease in afferent arteriolar vascular resistance, which would attenuate this vicious circle [20] . It has been shown by several groups, including our own, that brief anti-hypertensive treatment with ACEI or ARB at a critical period in the development of hypertension causes a sustained reduction in blood pressure and hypertensive end-organ damage [97] [98] . An interesting recent report by Smallgange et al. suggests that the these prolonged effects of ACEI can also be seen at a later age after the development of hypertension (i.e. at 15 weeks in the SHR), with just a two-week course of intensive treatment [100] . Moreover, since the sustained effects can be transferred to other SHR by kidney transplantation, the authors propose that regression of vascular remodeling in the renal afferent arterioles could be involved in these effects. These findings could be clinically important, since a short course of ACEI or ARB might theoretically attenuate the vicious circle of vascular remodeling leading to hypertension, and thereby prevent the development of hypertension in patients at risk. Two clinical studies (The TROPHY study [101] and DHyPP study [102] ) are now being performed to examine these issues, and if the results are promising, could signal the start of an era focusing on methods to manipulate vascular remodeling to prevent the development of hypertension and its complications.
CONCLUSION
Changes in the ECM play a central role in the processes of cardiac, vascular, and renal remodeling which may initially be adaptive, but ultimate result in a deterioration in tissue perfusion, structure and function, contributing directly to the morbidity and mortality associated with hypertension. Although the structural changes have been considered largely irreversible, the next challenge will be to reverse the maladaptive changes by pharmacological therapy. Understanding the mechanisms associated with ECM remodeling in hypertension may be useful for the selection of antihypertensive agents and strategies targeted specifically to prevent and reverse maladaptive structural changes and end-organ damage.
